HPV vaccine
AssigneeMerck Sharp & Dohme Corp.
InventorsMarian E. Gindy, John P. Bilello, Amy S. Espeseth, Andrew J. Bett, Tong-Ming Fu
Life of this patent
Estimating the term…
Abstract
The present disclosure provides, among other things, a pharmaceutical composition that includes a lipid nanoparticle adjuvant and an anti-human papillomavirus (HPV) comprising HPV virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82.
Claims17
A pharmaceutical composition comprising:
- virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types:
- 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82,
- a lipid nanoparticle (LNP) adjuvant, and
- a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising:
- (a) virus like particles (VLPs) of at least one type of human papillomavirus (HPV), wherein the at least one type of HPV is selected from the group consisting of HPV types:
- 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82;
- (b) about 100 μg to about 900 μg of an aluminum adjuvant;
- and
- (c) about 10 μg to about 200 mg of a lipid nanoparticle (LNP) adjuvant,
- wherein each of the HPV VLPs comprise recombinant L1 or recombinant L1+L2 protein;
- wherein each of the HPV VLPs are present in a concentration of about 10 μg to about 100 μg per 0.5 mL of the pharmaceutical composition;
- wherein the total HPV VLP concentration is between 10 μg and 2000 μg per 0.5 mL of the pharmaceutical composition;
- and
- wherein the HPV VLPs are adsorbed onto the aluminum adjuvant.
A method of inducing an immune response to a human papillomavirus (HPV) in a human patient comprising co-administering to the patient (a) a pharmaceutical composition comprising virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types:
- 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82 and (b) an LNP adjuvant.
A method of preventing infection of a human patient by a human papillomavirus (HPV) comprising co-administering to the patient (a) a pharmaceutical composition comprising virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types:
- 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82 and (b) an LNP adjuvant.
A kit comprising:
- (a) a human papilloma virus (HPV) vaccine comprising virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types:
- 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82;
- and
- (b) an LNP adjuvant.
A method of delivering a pharmaceutical composition that induces a neutralizing titer against an HPV antigen in a host comprising:
- (a) administering a pharmaceutical composition comprising:
- a lipid nanoparticle (LNP) adjuvant, and
- virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types:
- 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82,
- and
- (b) inducing a neutralizing titer against the HPV antigen in the host,
- where a single dose of the pharmaceutical composition provides enhanced or comparable neutralizing titers when compared to multiple doses of the same pharmaceutical composition when the anti-HPV composition is formulated without an adjuvant.
Dependencies are inferred from the claim text.